MoFo News Item

MoFo Advised Triastek on its Co-Development Agreement with Sperogenix Therapeutics

27 Apr 2021

Morrison & Foerster advised Triastek, Inc., a leading pharmaceutical company specializing in 3D printing of drug products, on its co‑development agreement with Sperogenix Therapeutics Limited, a company focusing on development and commercialization of rare disease medications in China, to jointly develop 3D-printed medicines for rare diseases. The collaboration widens the application of 3D-printed medicines and advances the development of rare disease research.

The MoFo team was led by Shanghai TTG/M&A partner Chuan Sun and Palo Alto Patent partner Janet Xiao. Beijing associate Xuezi Dan also provided support to the project.

Triastek submitted pre-IND to USFDA in 2019 and entered the IND stage in 2020, making it one of the two companies in the world with a USFDA submission in drug 3D printing. In addition to the co-development agreement, the MoFo IP team has worked closely with Triastek to build a robust patent portfolio, which positions the company to be a dominating player in the drug 3D printing field.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.